Case in point, the developers of a drug called, (I am not joking here) Lybrido, which is intended to increase sexual desire and response in women.

I don’t have a problem with this, though the idea that insufficient desire might be pathologized as hypoactive sexual-desire disorder (HSDD) is a bit troubling.

That being said, this following quote is even more troubling:

But of course swallowing a tablet can take us only so far. Chemically enhancing a woman’s desire might play out in all kinds of ways within a relationship. Some couples might feel closer, others might feel desolate because, despite more sex, their bond isn’t stronger. Wives might yearn for the old seductive efforts of their husbands, even if those gestures stopped working long ago. Women might feel yet more pressure to perform: Why not get that prescription? their partners might ask; why not take that pill? And men, if they are willing to confront the truth, might not be so happy about the reminder, as their partners reach for the pill bottle, that their women need chemical assistance to want them. All the agonies that have existed since the dawn of monogamy will still pertain, many of them coming down to the craving to feel special.

Beyond what might happen in millions of bedrooms, it’s even more difficult to foresee what societal transformations might be stirred. Just as with the birth-control pill, a foreboding not only about sex itself but also about female empowerment may be expressed in a dread of women’s sexual anarchy. Over the last decade, as companies chased after an effective chemical, there was fretting within the drug industry: what if, in trials, a medicine proved too effective? More than one adviser to the industry told me that companies worried about the prospect that their study results would be too strong, that the F.D.A. would reject an application out of concern that a chemical would lead to female excesses, crazed binges of infidelity, societal splintering.

“You want your effects to be good but not too good,” Andrew Goldstein, who is conducting the study in Washington, told me. “There was a lot of discussion about it by the experts in the room,” he said, recalling his involvement with the development of Flibanserin, “the need to show that you’re not turning women into nymphomaniacs.” He was still a bit stunned by the entrenched mores that lay within what he’d heard. “There’s a bias against — a fear of creating the sexually aggressive woman.”

Yes, giving 70 years erections to unleash upon the rest of society is a great profit center, but if women start wanting sex, it can create “societal splintering”.

So, men suddenly want to copulate with anything with a hole in it: Good.

Women wanting to have sex: Scary.

Someone needs to get their heads out of their ass.